ObsEva
IPO
- Employees
- 11–50
- Founded
- 2012
- Business Model
- B2B
- Total Funding
- $111.0M
- Last Round
- $20.0M Venture RoundSep 2020
About
Founded in 2012 and headquartered in Geneva, Switzerland, ObsEva SA (formerly Nasdaq: OBSV) was a biopharmaceutical company focused on developing and commercializing novel therapies for conditions in women's reproductive health and pregnancy. The company's pipeline included linzagolix (GnRH receptor antagonist for uterine fibroids and endometriosis) and ebopiprant (for preterm labor). ObsEva completed an IPO in 2018. Due to financial difficulties, the company undertook a strategic reorganization in 2023 and ultimately wound down operations and laid off all employees in February 2024.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account